Strategic partnerships EVERY Company's recent and ongoing collaborations with Huvepharma, Investin Abu Dhabi, and ADIO indicate a strong channel for co-developed fermentation-based protein solutions. Sales opportunities exist in co-marketing, contract manufacturing, and joint ventures with large agri/food players seeking animal-free ingredient capabilities.

Expansion momentum A significant manufacturing expansion announced with Huvepharma signals increased capacity and reliability for large-scale customer programs. Target opportunities include supplying high-volume egg protein ingredients to food manufacturers, retailers, and brands seeking scalable alt-protein solutions.

Strategic funding Recent Series D funding of 55 million and high-profile backers suggest strong investor confidence and future growth. Leverage this to pursue marquee customers and long-term supply agreements, emphasizing innovation cadence, regulatory readiness, and sustainability benefits.

Product-market fit Pervasive application across bars, beverages, bakery, alt-meat, and novel foods with nature-equivalent egg proteins offers cross-category upsell. Prioritize multi-application deals with CPGs and private-label manufacturers seeking functional proteins to replace conventional eggs.

Global reach Affiliations with Abu Dhabi’s ADIO and international partners imply willingness to export and establish regional production. Sales plays should target global brands aiming for regionalized sourcing, with emphasis on sustainability credentials, land and water savings, and reduced emissions.